| Allentown Internal Medicine Pc | |
|
1280 Yardville Allentown Rd Allentown NJ 08501 | |
| (609) 259-3635 | |
| (609) 259-9508 |
| Full Name | Allentown Internal Medicine Pc |
|---|---|
| Speciality | Internal Medicine |
| Location | 1280 Yardville Allentown Rd, Allentown, New Jersey |
| Authorized Official Name and Position | James A Webb (PHYSICIAN) |
| Authorized Official Contact | 6092593635 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Allentown Internal Medicine Pc 1280 Yardville Allentown Rd Allentown NJ 08501 Ph: (609) 259-3635 | Allentown Internal Medicine Pc 1280 Yardville Allentown Rd Allentown NJ 08501 Ph: (609) 259-3635 |
| NPI Number | 1598987117 |
|---|---|
| Provider Enumeration Date | 05/03/2007 |
| Last Update Date | 07/02/2010 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598987117 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA04584900 (New Jersey) | Primary |
News Archive
"Super Bowl Sunday is the second highest day for food consumption," says Lisa Cimperman, RD, clinical dietitian at University Hospitals Case Medical Center, "right behind Thanksgiving Day."
ViroPharma Incorporated today announced the availability of final data from Open-Label studies of Cinryze (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov.
As the global spread of the Zika virus continues, efforts are underway to halt the disease's transmission.
Accuray Incorporated, a global leader in the field of radiosurgery, today announced that the first CyberKnife VSI System to be installed in Europe was placed at the Leon-Berard Cancer Multidisciplinary Center in Lyon, France. The CyberKnife VSI System is the newest addition to the CyberKnife product family.
Taro Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has informed the Company that after a February 2011 re-inspection of its Canadian manufacturing facility, the site has an acceptable regulatory status. Therefore, the issues noted in the February 5, 2009 warning letter are considered to be resolved.
› Verified 6 days ago